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Background: Diabetes increases the risk of heart failure but the underlying mechanisms leading to diabetic
cardiomyopathy are poorly understood. Left ventricle diastolic dysfunction (LVDD) is one of the earliest cardiac
changes in these patients. We aimed to evaluate the association between LVDD with insulin resistance, metabolic
syndrome (MS) and diabetes, across the diabetic continuum.
Methods: Within a population-based study (EPIPorto), a total of 1063 individuals aged ≥45 years (38% male,
61.2 ± 9.6 years) were evaluated. Diastolic function was assessed by echocardiography, using tissue Doppler
analysis (E’ velocity and E/E’ ratio) according to the latest consensus guidelines. Insulin resistance was assessed
using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) score.
Results: The HOMA-IR score correlated to E’ velocity (ρ = −0.20;p < 0.0001) and E/E’ ratio (ρ = 0.20; p < 0.0001).
There was a progressive worsening in E’ velocity (p for trend < 0.001) and in E/E’ ratio across HOMA-IR quartiles
(p for trend <0.001). Individuals in the highest HOMA-IR quartile were more likely to have LVDD, even after
adjustment for age, sex, blood pressure and body mass index (adjusted OR: 1.82; 95% CI: 1.09-3.03). From individuals
with no MS, to patients with MS and no diabetes, to patients with diabetes, there was a progressive decrease in E’
velocity (11.2 ± 3.3 vs 9.7 ± 3.1 vs 9.2 ± 2.8 cm/s; p < 0.0001), higher E/E’ (6.9 ± 2.3 vs 7.8 ± 2.7 vs 9.0 ± 3.6; p < 0.0001) and
more diastolic dysfunction (adjusted OR: 1.62; 95% CI: 1.12-2.36 and 1.78; 95% CI: 1.09-2.91, respectively).
Conclusions: HOMA-IR score and metabolic syndrome were independently associated with LVDD. Changes in diastolic
function are already present before the onset of diabetes, being mainly associated with the state of insulin resistance.
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Subclinical left ventricle diastolic dysfunction (LVDD) is
common in the community [1] and is recognized as an
important predictor of heart failure [2] and long-term
mortality [3]. Current heart failure guidelines [4] give
special emphasis to the early detection of these asymp-
tomatic changes of left ventricle function and the identi-
fication of its main risk factors.* Correspondence: fontes.carvalho@gmail.com
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article, unless otherwise stated.Epidemiological studies have associated diastolic func-
tion with aging, hypertension and myocardial ischemia
[1]. Besides, more recent data have also demonstrated an
independent association between diastolic function and
obesity [5], especially with abdominal obesity [6] and vis-
ceral fat mass [7]. Insulin resistance can be one of the
important pathophysiological links involved in this asso-
ciation [8,9]. Several studies have suggested that LVDD
is one of the earliest signs of myocardial involvement in
type 2 diabetes mellitus (T2DM) [10], being a key com-
ponent of diabetic cardiomyopathy [11].
More recently, it was suggested that changes in dia-
stolic function precede the onset of diabetes, being
already present in pre-diabetic patients [12,13], whichCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Metabolic syndrome (MS), or insulin resistance syn-
drome, is a cluster of cardiovascular risk factors shown
to act synergistically to increase the risk of adverse car-
diovascular events [14], but also inducing subclinical
changes in cardiac structure and function. Indeed, pa-
tients with metabolic syndrome also have an increased
prevalence of LVDD [15,16], frequently with a subclin-
ical course [17].
In this study, our aim was to evaluate, at the popula-
tion level, the association between insulin resistance and
LVDD in different stages of the diabetic continuum.
Methods
Study population
Participants were selected within the first follow-up of a
cohort, representative at baseline of the adult population
of Porto, Portugal — the EPIPorto cohort study. In
1999–2003, the cohort assembly was made by random-
digit dialing, using households as the sampling frame,
followed by random selection of one person aged 18
years or older in each household. Refusals were not
substituted within the same household. The proportion
of participation was 70%. At baseline, 2485 participants
were recruited. Between October 2006 and July 2008,
participants aged 45 years or over were eligible to a sys-
tematic evaluation of parameters of cardiac structure
and function, which included a cardiovascular clinical
history, physical examination, detailed anthropometric
evaluation, collection of fasting blood sample and a
transthoracic echocardiogram. Among 2048 cohort
members in the eligible age range at this time, 134
(6.5%) had died, 198 (9.7%) refused to be re-evaluated
and 580 (28.3%) were lost to follow-up (unreachable by
telephone or post). From this analysis we excluded 73
patients with previous myocardial infarction, percutan-
eous or surgical revascularization, prior cardiac surgery
or significant (moderate to severe) valvular heart disease.
Patients with type 1 diabetes (n = 6) were excluded from
the analysis.
Written informed consent was obtained from all the
individuals and the local ethics committee (Comissão
Ética Centro Hospitalar S. João) approved the study. The
investigation conforms to the principles outlined in the
Declaration of Helsinki.
Clinical variables definitions
Hypertension was defined as systolic blood pressure
(SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥
90 mm Hg at the time of the visit (mean of 3 readings)
or use of antihypertensive medication. T2DM was de-
fined as fasting blood glucose ≥126 mg/dl or the pa-
tient’s self-reported history of diabetes or use of diabetes
medications. Hypercholesterolemia was defined as totalserum cholesterol ≥220 mg/dl or the use of lipid- lower-
ing treatment. Obesity was defined as body mass index
(BMI) ≥ 30 kg/m2 and central obesity as waist circumfer-
ence >102 cm in men and >88 cm in women. Metabolic
syndrome was defined according to the American Heart
Association updated National Cholesterol Education
Program Adult Treatment Panel III (AHA/NCEP) criteria
[18]. Although there are several definitions for metabolic
syndrome, we used this definition because it showed the
strongest association with cardiovascular disease in the
Portuguese population [19].
MS was diagnosed if any 3 of the following were
present: central obesity (WC 102 cm in men and 88 cm
in women), raised triglycerides (≥150 mg/dL or fibrates
intake), reduced HDL-C (< 40 mg/dL in males and 50
mg/dL in females), raised blood pressure (SBP ≥ 130
mmHg or DBP ≥ 85 mmHg or anti-hypertensive treat-
ment) or raised fasting plasma glucose (FPG ≥ 100 mg/
dL or previously diagnosed T2DM). We defined 3 popu-
lations of interest in the diabetic continuum: individuals
with no MS, patients with MS without T2DM and pa-
tients with T2DM.
Analytical data
A fasting venous blood sample was obtained in the
morning for measurement of glucose, total cholesterol,
LDL, HDL, triglycerides and high-sensitivity C-reactive
protein (by immunonephelometry). For insulin measure-
ment the blood was immediately centrifuged and the
plasma stored at −20°C, for later measurement. Insulin
resistance was assessed using the Homeostasis Model
Assessment of Insulin Resistance (HOMA-IR) score in
subjects without a history of T2DM before inclusion
into the study. The HOMA score was calculated from
the formula [20]: HOMA-IR = fasting glucose (mg/dl) ×
insulin (μU/ml)/405.
Echocardiography data
All echocardiographic studies were acquired using the
same equipment (Hewlett-Packard Sonos 5500). Images
were stored on videotape for posterior offline analysis by
two experienced cardiologists, blinded to clinical data.
Cardiac chambers dimensions, volumes and left ven-
tricular mass were measured according to current rec-
ommendations [21], and indexed to body surface area.
Diastolic function was assessed according to the recent
consensus guidelines on diastolic function evaluation
[22] measuring mitral inflow velocities (E-wave, A wave,
E/A ratio) and deceleration time (DT) using pulsed-
wave (PW) Doppler in the apical four-chamber view.
Velocities were recorded at end-expiration and averaged
over three consecutive cardiac cycles. Isovolumetric relax-
ation time (IVRT) was also assessed accordingly. PW
tissue-Doppler velocities were acquired at end-expiration,
Table 1 Characteristics of the study participants
Total
n = 1063
Age, years 62.2 ± 10.6
Male sex, n (%) 394 (37.1)
Cardiovascular risk factors
Hypertension, n (%) 361 (34.8)
Diabetes, n (%) 123 (11.8)
Dyslipidemia, n (%) 570 (54.9)
Obesity, n (%) 258 (24.3)
Systolic blood pressure,
mmHg
133 ± 20
Diastolic blood pressure,
mmHg
78 ± 11
BMI, Kg/m2 27.5 ± 4.6
Waist perimeter/height,
cm/cm
0.58 ± 0.07
Hip perimeter/height,
cm/cm
0.64 ± 0.07
Waist-to-hip ratio 0.92 ± 0.08
Analytical data
Total cholesterol, mg/dL 220 ± 52
HDL, mg/dL 62 ± 44
LDL, mg/dL 134 ± 52
Triglycerides, mg/dL 152 ± 443
Glucose, mg/dL 104 ± 47
C-reactive protein, mg/dL 0.19 (0.09-0.4)
HOMA-IR score 1.09 (0.62-1.86)
Echocardiography
Septum, mm 8.7 ± 1.5
Posterior wall, mm 7.9 ± 1.3
LV mass index, g/m2 80.2 ± 21.0
Left atrium volume index,
ml/m2
29.2 ± 10.4
LV end-diastolic volume,
ml/m2
66.5 ± 16.9
LV end-systolic volume,
ml/m2
27.3 ± 10.2
Ejection fraction, % 60.2 ± 6.8
E wave, cm/s 71.4 ± 15.8
A wave, cm/s 78.6 ± 19.9
E/A ratio 0.96 ± 0.32
Deceleration time, ms 238.1 ± 56.9
IVRT, ms 92.0 ± 16.1
E’ velocity, cm/s 10.5 ± 3.3
E/E’ ratio 7.4 ± 2.7
LVDD grade
Normal, n (%) 792 (76.3)
Mild, n (%) 151 (14.5)
Table 1 Characteristics of the study participants
(Continued)
Moderate, n (%) 92 (8.9)
Severe, n (%) 3 (0.3)
Undetermined 25
Data are presented as mean ± standard deviation for continuous variables with
normal distribution, median and 25th and 75th percentiles (P25-P75) for variables
with non-normal distribution and count (percentage) for categorical variables.
(BMI – body mass index; s – seconds; DD – diastolic dysfunction; IVRT –
isovolumetric relaxation time; LV – left ventricle; LVDD – left ventricle
diastolic dysfunction).
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tioned at the lateral mitral annulus, measuring early dia-
stolic (E’) and late diastolic (A’) velocities and calculating
the E/E’ ratio. Patients were categorized into normal dia-
stolic function or LVDD grades I (mild LVDD), II (moder-
ate LVDD) and III (severe LVDD), by two independent
cardiologists according to the criteria in the consensus
guidelines [22]. In case of discordance, each case was
discussed individually, and if doubt persisted no grade was
endorsed. LV systolic function was evaluated by determin-
ation of LV ejection fraction using the modified Simpson’s
rule from biplane 4-chamber.Statistical analysis
Statistical analyses were performed using STATA version
12 (STATA Corp, TX, USA). Data are expressed as mean
± standard deviation for quantitative variables with normal
distribution, as median and 25th and 75th percentiles
(P25-P75) for variables with non-normal distribution or as
number (n) and percentage (%) for categorical variables.
Pearson coefficient (r) was calculated to assess the correl-
ation of two normally distributed continuous variables and
the Spearman correlation (ρ) was used when the variables
were non-normally distributed. The trend across categor-
ical variables was tested with the nptrend command,
which is an extension of the Wilcoxon rank-sum test. Uni-
variate and multivariate logistic regression analysis was
performed to predict the presence of LVDD. The variables
included in the multivariate model based on previous
knowledge were age, gender, systolic blood pressure and
BMI. An interaction term was added to the model to as-
sess effect modification by sex, which was not confirmed.Results
Patient characteristics
In this study, 1063 individuals were included, 38% were
male, with a mean age of 62.4 ± 10.6 years. The preva-
lence of MS according to the AHA/NCEP criteria was
41.8% and 11.9% had diabetes. Only 16 patients had
T2DM without fulfilling the criteria of MS. Table 1
shows the clinical, anthropometric, analytical and echo-
cardiographic characteristics of the study sample. The
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23.7%: 14.5% had mild diastolic dysfunction and 9.2%
had moderate or severe diastolic dysfunction. In 25 pa-
tients (2.4%) it was not possible to determine LVDD
grade due to atrial fibrillation or fusion of the E/A mitral
flow pattern. Regarding medication use, 24.6% were
doing renin-angiotensin axis blockers, 7.1% were taking
calcium channel blockers, 12.1% were on diuretics and
22.8% were taking statins.
Insulin resistance and LVDD
The HOMA-IR score was inversely correlated to lateral E’
velocity (Spearman’s ρ = −0.20; p < 0.001) and positively
correlated to E/E’ ratio (Spearman’s ρ = 0.20; p < 0.001).
According to HOMA-IR quartiles, higher insulin resist-
ance was associated with lower E’ velocity and higher E/E’
ratio, as shown in Table 2 and Figures 1 and 2.
We observed a stepwise increase in HOMA-IR score
according to the grades of diastolic function. HOMA-IR
score increased from 0.95 (P25-75: 0.56-1.69) in individ-
uals with normal diastolic function, to 1.30 (P25-75:
0.70-2.03) in patients with grade I diastolic dysfunction
and to 1.59 (P25-75: 0.83-2.41) in patients with moder-
ate/severe diastolic dysfunction (p < 0.001).
Table 2 shows the association of diastolic function pa-
rameters with insulin resistance (HOMA-IR) and dia-
betes status. We observed a significant trend for lower E’
velocity and higher E/E’ ratio across HOMA-IR quar-
tiles. Compared to the first quartile, individuals in the
highest HOMA-IR quartile showed a 1.82-fold increased
odds of LVDD (95% CI: 1.09-3.03), as detailed in
Table 3.
Metabolic syndrome, T2DM and LVDD
First, we observed a significant increase in HOMA-IR
score from patients without MS (0.80; P25-75: 0.44-1.28)Table 2 Diastolic dysfunction parameters according to quarti
E’ velocity
Insulin resistance
(HOMA-IR score)
Quartile 1 11.3 ± 3.3
Quartile 2 10.7 ± 2.9
Quartile 3 10.1 ± 3.6
Quartile 4 9.8 ± 3.0
No Metabolic Syndrome (n = 571) 11.2 ± 3.3
Metabolic Syndrome without T2DM (n = 331) 9.7 ± 3.1
Metabolic Syndrome with T2DM (n = 123) 9.2 ± 2.8
p for trend p < 0.001
DT - deceleration time; T2DM - type 2 diabetes mellitus; HOMA-IR - Homeostasis Mo
Results are presented as mean ± standard deviation.to patients with MS without T2DM (1.60; P25-75: 0.91-
2.25) and to patients with MS and T2DM (2.56; P25-75:
1.55-4.64), p < 0.001.
Patients with MS or T2DM showed lower E’ velocity
and increased E/E’ ratio. Furthermore, as shown in
Table 2, there was a significant trend for progressively
lower E’ velocity and E/A ratio and higher E/E’ ratio and
DT when comparing individuals without MS, to patients
with MS not including T2DM and to patients with MS
and T2DM.
The prevalence of diastolic dysfunction was 16.3% in
the patients without MS, 32.6% in patients with MS and
no T2DM and 36.6% in patients with MS and T2DM (p
for trend < 0.001; Table 3). After adjusting for age, sex,
SBP and BMI, patients with MS and no T2DM showed a
1.62 (95% CI: 1.12-2.36) increased odds of having LVDD
and patients with T2DM showed an OR of 1.78 (95% CI:
1.09-2.91). There was no statistically significant differ-
ence in the odds of LVDD between patients with MS
and no T2DM compared to patients with T2DM (p =
0.696). Also, T2DM was not associated with an increased
odds of LVDD (adjusted OR: 1.38; 95% CI: 0.88-2.16)
after including in the comparator group both patients
with and without MS. We did not find any significant
interaction according to gender for the association be-
tween diastolic dysfunction with insulin resistance,
metabolic syndrome or T2DM.
Discussion
In this population-based study, we showed that insulin
resistance is associated with left ventricular diastolic
dysfunction. There was also a progressive worsening of
diastolic function parameters (E’ velocity and E/E’ ratio)
from individuals without MS, to patient with MS with-
out T2DM and to patients with fully established T2DM.
Metabolic syndrome was significantly associated withles of insulin resistance and metabolic syndrome status
Diastolic function parameters
E/E’ ratio E/A ratio DT
6.8 ± 2.6 1.03 ± 0.37 232.8 ± 52.8
7.1 ± 2.3 0.97 ± 0.28 233.2 ± 50.4
7.6 ± 2.7 0.92 ± 0.27 240.8 ± 69.5
8.1 ± 3.1 0.92 ± 0.35 245.5 ± 54.3
6.9 ± 2.3 1.01 ± 0.32 232.3 ± 56.9
7.8 ± 2.7 0.88 ± 0.25 248.4 ± 57.2
9.0 ± 3.6 0.95 ± 0.46 237.9 ± 52.7
p < 0.001 p < 0.001 p = 0.002
del Assessment of Insulin Resistance.
Figure 1 E’ velocity according to insulin resistance quartiles.
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age, blood pressure and body mass index.
The association between diastolic dysfunction and insulin
resistance
In most patients with glucose metabolism disturbances,
insulin resistance is the key pathophysiological mechan-
ism. In this study we found that individuals with higher
insulin resistance had worse diastolic function parame-
ters and a significantly increased risk of LVDD, which
was independent of other determinants of diastolic func-
tion. Until now, few other studies have analyzed theFigure 2 E/E’ ratio according to insulin resistance quartiles.association between insulin resistance and changes in
cardiac function, namely with diastolic dysfunction. In a
group of selected non-diabetic patients undergoing
elective coronary angiography, Dinh et al. also found
that insulin resistance was independently associated with
LVDD [23] and the same has been observed in a small
study of patients with aortic valve sclerosis [24]. Two
other studies have demonstrated changes in diastolic
function across the diabetic continuum, including in pre-
diabetic patients [12,13]. Altogether these data suggest
that subclinical changes in myocardial diastolic function
are already present before the onset of T2DM, being
Table 3 Crude and adjusted odds ratios for the presence of any grade of diastolic dysfunction according to quartiles
of insulin resistance and metabolic syndrome status
Prevalence of LVDD n (%) Crude OR (95% CI) Adjusted OR* (95% CI)
Insulin resistance
(HOMA-IR score)
Quartile 1 35 (14.9%) Reference Reference
Quartile 2 42 (18.6%) 1.30 (0.80-2.13) 1.08 (0.63-1.86)
Quartile 3 70 (29.3%) 2.37 (1.50-3.73) 1.88 (1.12-3.14)
Quartile 4 89 (30.6%) 2.52 (1.63-3.90) 1.82 (1.09-3.03)
No Metabolic Syndrome (n = 571) 93 (16.3%) Reference Reference
Metabolic Syndrome without T2DM (n = 331) 108 (32.6%) 2.54 (1.85-3.50) 1.62 (1.12-2.36)
Metabolic Syndrome with T2DM (n = 123) 45 (36.6%) 3.04 (1.98-4.67) 1.78 (1.09-2.91)
T2DM: type 2 diabetes mellitus; LVDD: left ventricular diastolic dysfunction; HOMA-IR - Homeostasis Model Assessment of Insulin Resistance;
OR (95% CI) – odds ratio with 95% confidence interval.
*Variables included in the model: age (continuous), sex, systolic blood pressure (continuous) and body mass index (continuous).
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not only to sustained hyperglycemia.
Metabolic syndrome, also known as insulin resistance
syndrome, is common, affecting more than 20% of the
adult population of United States and Europe [25]. Insulin
resistance is central to the pathophysiology of MS, being
associated with a pro-inflammatory, pro-thrombotic and
oxidative state and increased risk of atherosclerotic cardio-
vascular disease [14]. In this study we showed that MS is
also independently associated with subclinical changes in
myocardial function, namely with LVDD. Compared to
individuals without MS, patients with MS had worse
diastolic function parameters, including reduced E’
velocity, which is a marker of LV relaxation, and
higher E/E’ ratio, which reflects increased LV filling
pressures. Moreover, MS was associated with a 1.62-
increased odd of LVDD independently of age, sex,
blood pressure and body mass index. These data are in
accordance with the observations of other smaller
studies [15,16,26,27], that also showed a progressive
worsening of diastolic function parameters according
to the number of criteria for metabolic syndrome
[15,16]. Several pathophysiologic mechanisms can be
involved in the association between insulin resistance
and LVDD [28]. In the heart, insulin stimulates glu-
cose uptake and oxidation and, although it increases
fatty acid uptake, it inhibits fatty acid utilization for
energy. Therefore insulin resistance results in a reduc-
tion of myocardial energy supply due to changes in
substrate utilization from glucose to free fatty acids
[11,29]. Other involved mechanisms include increased
myocardial interstitial fibrosis [30], activation of sym-
pathetic nervous system [31], increased afterload and
impaired ventricular-vascular coupling due to arterial stiff-
ness [32,33], endothelial dysfunction [34], increased
myocardial oxidative stress [35] or secretion of fatty
acid-binding protein 4 [36].Diastolic dysfunction and type 2 diabetes mellitus
At the other end of the diabetic continuum, it is sug-
gested that diabetes can affect cardiac structure and
function in the absence of changes in blood pressure or
coronary artery disease, a condition called diabetic car-
diomyopathy [11,37]. In humans, LVDD is considered
the earliest manifestation of diabetic cardiomyopathy,
preceding the development of systolic dysfunction [11].
In our study, we observed that the greatest difference in
diastolic function parameters occurs between individuals
without MS and patients with metabolic syndrome.
However, patients with T2DM had an additional worsen-
ing in diastolic function parameters, such as E’ velocity
and E/E’ ratio, and a further increased prevalence of
LVDD. It is known that the pathogenesis of diabetic
cardiomyopathy is multifactorial [11] and beyond the
changes associated with insulin resistance, sustained
hyperglycemia also increases glycation of interstitial
proteins such as collagen by deposition of advanced
nonenzymatic glycation end products (AGE) in the
extracellular matrix [38], resulting in a further increase
in myocardial stiffness. Reinforcing the possibility of an
additional “glucotoxic” effect of hyperglycemia on car-
diac function, a large study of patients with type 1 dia-
betes – where insulin resistance is not an important
pathophysiological mechanism – showed that incident
heart failure was associated with HbA1c and the rate of
glycemic control [39].
Future research and implications to clinical practice
Subclinical LVDD is recognized as an important pre-
dictor of heart failure [40] and long-term mortality
[1,41]. Therefore, the early identification and correction
of the main determinants of subclinical diastolic dys-
function, such as insulin resistance, can be important to
reduce morbidity and mortality in these individuals [4].
This can be especially important in the prevention of
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known as diastolic heart failure), a disease where no
therapy has been shown to significantly improve the
prognosis [42].
All these data suggest that the deterioration of dia-
stolic function is already present in an early phase of
glucose disturbance metabolism, before the onset of dia-
betes, being mainly associated with insulin resistance
and not only with sustained hyperglycemia. Interestingly,
several studies have shown that insulin resistance, with
or without diabetes mellitus, predicted incident heart
failure independently of other established risk factors
[8,43,44]. On the contrary, only few studies [45] have
clearly demonstrated an independent association be-
tween diabetes and incident heart failure, especially be-
cause this association is confounded by the simultaneous
presence of other risk factors. Most of these studies have
compared diabetic versus non-diabetic individuals, in-
cluding in the comparator group individuals with insulin
resistance and metabolic syndrome, which can partly
attenuate the differences in heart failure risk.
Future research will determine if the administration of
drugs that increase insulin sensitivity can improve
myocardial structure and function, particularly dia-
stolic function. Recently, in animal models of insulin
resistance, metformin reduced myocardial fibrosis, at-
tenuated cardiac remodeling and the progression to
heart failure [46,47]. This “cardioprotective” effect of met-
formin can be due to the interference with TGF-beta sig-
naling pathway and activation of the AMP-kinase
signaling cascade [48,49]. A new phase II clinical trial is
now evaluating if the administration of metformin im-
proves diastolic function in patients with metabolic syn-
drome and LVDD [50].
Finally, both insulin resistance and metabolic syn-
drome are closely associated with obesity. Recent data
have demonstrated an independent association be-
tween LVDD and obesity [5], especially with abdom-
inal obesity [6] and visceral fat mass [7]. Therefore, it
has been proposed that insulin resistance was one of
the important pathophysiological links involved in this as-
sociation between obesity and LVDD [8,9]. Our data also
show that the association between insulin resistance and
LVDD is independent of body mass index, which is in ac-
cordance with the study by Ayalon et al. [27].
Strengths and limitations
Strengths of this study include the relatively large sample
of individuals from the general population without other
cardiac diseases and the contemporaneous assessment of
cardiac diastolic function using tissue Doppler and using
the integrated consensus criteria for diastolic dysfunc-
tion evaluation [22]. The latest consensus recommenda-
tions on LV diastolic function assessment strongly advisein favor of the systematic use of tissue Doppler-derived
early mitral annulus velocity (E’ wave) and E/E’ ratios, as
the main echocardiographic parameters for diastolic
function evaluation. It is known that the E’ wave is a
preload-independent index of LV relaxation, being
closely related with invasively determined tau (the time
constant of isovolumic pressure decline). Moreover, an
E/E’ ratio > 15 strongly correlates with invasively deter-
mined increased LV filling pressures [22]. On the con-
trary, E/A ratio and DT, which are derived from the
evaluation of mitral inflow velocities, have several limita-
tions in the evaluation of diastolic function, especially
because they are dependent on loading conditions and on
heart rate. Moreover, these two variables have a U-shaped
relation with the severity of diastolic dysfunction, which
explains why E/A ratio does not decrease stepwise accord-
ing to the groups of insulin resistance.
The main limitation is the cross-sectional design,
which partially limits comments on causality, as this
would be more robust in a prospective design. Although
we have excluded patients with clinical signs of coronary
artery disease, we did not perform any stress test to ex-
clude myocardial ischemia, which is one determinant of
diastolic dysfunction. In this study, patients were not
submitted to oral glucose tolerance test. Finally, detailed
analysis of left ventricle function using new strain and
strain rates techniques was not performed in this study.
Conclusion
Insulin resistance and metabolic syndrome are associ-
ated with diastolic dysfunction independently of age,
blood pressure and body mass index. These data suggest
that subclinical changes in myocardial diastolic function
are already present before the onset of diabetes, being
associated mainly with the state of insulin resistance
and not only to sustained hyperglycemia. Future re-
search will determine if improving insulin resistance
using insulin-sensitizers or lifestyle changes can im-
prove diastolic function.
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